Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 559 clinical trials
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a

  • 49 views
  • 24 Jan, 2021
  • 6 locations
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

The aim of this study is to make preliminary assessment of PD-L1 and other immune related biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with recurrent

measurable disease
recurrent disease
platelet count
glioblastoma multiforme
corticosteroids
  • 0 views
  • 25 Jan, 2021
  • 1 location
SX-682 and Nivolumab for RAS Mutated Microsatellite Stable Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)

The primary objectives are to determine the safety profile of SX-682 alone and in combination with nivolumab in subjects with refractory RAS mutated MSS mCRC, including the maximum dose that can

  • 0 views
  • 24 Feb, 2021
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

increase the success of immunotherapy, immuno-oncology community develops combinations approaches. The aim of these project is to evaluate the efficacy of Nivolumab plus a novel CD4Th1 inducer anti

  • 0 views
  • 27 Jan, 2021
  • 7 locations
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4). Additionally, the investigators will study the impact of the combination immunotherapy on peripheral T cell activation, as well as immune response in the

  • 25 views
  • 27 Jan, 2021
  • 2 locations
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

modality chosen. Patients will be randomized to either the control arm or the experimental arm. The control arm will receive mFOLFOX6 every 2 weeks for 4 cycles concurrently with Nivolumab. The

neutrophil count
systemic chemotherapy
platelet count
aptt
metastasis
  • 3 views
  • 25 Jan, 2021
  • 7 locations
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma.

vascular endothelial growth factor
vegf
measurable disease
systemic therapy
karnofsky performance status
  • 0 views
  • 26 Jan, 2021
  • 1 location
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo) and talazoparib (also known as Talzenna) are when given as a combination treatment for

  • 0 views
  • 25 Jan, 2021
  • 1 location
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.

This proof of concept trial aims to assess whether the combination of IRE with Nivolumab is safe and effective to treat metastatic pancreatic cancer, based on the available preliminary evidence

neutrophil count
measurable disease
folfirinox
platelet count
gemcitabine
  • 0 views
  • 26 Jan, 2021
  • 4 locations
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer

  • 0 views
  • 24 Jan, 2021
  • 1 location